Discovery of chiral N-2′-aryletheryl-1′-alkoxy-ethyl substituted arylisoquinolones with anti-inflammatory activity from the nucleophilic addition reactions of the thiophenols and oxazolinium

Bo Li,Heng Li,Zhengdan Zhu,Caigui Xiang,Zhijian Xu,Chen Fan,Yitian Zhao,Chunlan Feng,Haiguo Sun,Yong Zhang,Tingting Cai,Wei Tang,Weiliang Zhu
DOI: https://doi.org/10.1016/j.ejmech.2021.113583
IF: 7.088
2021-10-01
European Journal of Medicinal Chemistry
Abstract:<p>Herein we disclosed the novel nucleophilic addition reactions of the thiophenols and oxazolinium (<strong>DCZ0358</strong>) to produce N-2'-aryletheryl-1'-alkoxy-ethyl substituted arylisoquinolones. After evaluating the anti-inflammatory activity <em>in vitro</em>, <strong>2d</strong> was found having significant anti-TNFα activity. Through the amplified synthesis of <strong>2d</strong>, four monomers (<strong>3a-b</strong> and <strong>4a-d</strong>) were obtained by chiral separation of the product. The reaction mechanism was proposed and explored by the control experiments. However, only the R-stereoisomers <strong>3b</strong> and <strong>4b</strong> have significant anti-TNFα activity <em>in vitro</em> (IC<sub>50</sub> = 56 and 14 nM, respectively). Moreover, <strong>4b</strong> exerts potent therapeutic effects on ulcerative colitis <em>in vivo</em> (30 mg/kg bw, qd, i.g.). The subsequent bio-target exploration of compound <strong>4b</strong> <em>via</em> molecular docking and the experimental validation disclosed that <strong>4b</strong> has 3-fold selectivity of binding activity on estrogen receptor (ER) beta (β) (Ki = 760.86 nM) vs. alpha (α) (Ki = 2320.58 nM). Thus, it provides a novel type of non-steroidal leads for developing anti-inflammatory drugs.</p>
chemistry, medicinal
What problem does this paper attempt to address?